Study on IV Telisotuzumab Adizutecan with Bevacizumab vs. Standard Treatment for Advanced Colorectal Cancer
Sponsor: AbbVie
ClinicalTrials ID:NCT07525206
This clinical trial is comparing a new drug combination, telisotuzumab adizutecan with bevacizumab, to the standard treatment for adults with advanced colorectal cancer that has not responded to previous treatments.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
Colorectal cancer is one of the most common cancers worldwide. This study aims to compare the effects and side effects of a new drug combination, telisotuzumab adizutecan with bevacizumab, against the standard treatment of LONSURF (trifluridine and tipiracil) with bevacizumab in adults with advanced colorectal cancer that has not responded to other treatments. Participants will be randomly assigned to one of two groups: one group will receive the new drug combination, and the other will receive the standard treatment. The study will involve about 700 participants across 125 locations globally and will last approximately 36 months. Participants will have regular check-ups, including medical assessments, blood tests, and questionnaires, to monitor the treatment's effects and any side effects.
Eligibility Criteria
Inclusion Criteria
- Must agree to participate by signing a consent form approved by an Ethics Committee.
- Must have a life expectancy of at least 12 weeks, as assessed by the study doctor.
Exclusion Criteria
- Cannot have previously received treatments targeting c-Met or other investigational drugs.
- Cannot have a history of allergic reactions to bevacizumab or similar drugs.
- Cannot have allergies to products made from Chinese Hamster Ovary cells or similar antibodies.
- Cannot have a history of significant drug or alcohol abuse in the past 6 months.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| Astera Cancer Care /ID# 279532 | 08816-4096 | East Brunswick | New Jersey |
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.